ReviewFrontiers in pharmacology2022

Learn from failures and stay hopeful to GPR40, a GPCR target with robust efficacy, for therapy of metabolic disorders.

Hong-Ping Guan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.